Chk2 Antibody (DCS-270): sc-56296
- Chk2 Antibody (DCS-270) is a mouse monoclonal IgG2a κ, cited in 14 publications, provided at 200 µg/ml
- raised against a Chk2 fusion protein of human origin
- recommended for detection of Chk2 of human origin by WB, IP, IF and IHC(P)
- See Chk2 (A-11): sc-17747 for Chk2 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG2a BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for Chk2 Antibody (DCS-270) for WB and IHC(P) applications. These reagents are now offered in bundles with Chk2 Antibody (DCS-270) (see ordering information below).
QUICK LINKS
Chk2 Antibody (DCS-270) is a mouse monoclonal IgG2a antibody that detects Chk2 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Chk2 plays a critical role in the cellular response to DNA damage, functioning as a key regulator in the G2 DNA damage checkpoint. Upon DNA damage, Chk2 is activated and phosphorylates Cdc25C, which inhibits its phosphatase activity, thereby preventing the activation of cyclin-dependent kinases and blocking the progression of mitosis. This mechanism is vital for maintaining genomic stability, as it allows the cell time to repair DNA before division, thus preventing the propagation of damaged DNA. Additionally, Chk2 interacts with various proteins involved in the DNA damage response, including p53, further underscoring its importance in tumor suppression and cellular integrity. Anti-Chk2 antibody (DCS-270) is an essential tool for researchers studying cell cycle regulation and the mechanisms of DNA damage repair in human cells.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Chk2 Antibody (DCS-270) References:
- The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. | Chen, Y. and Poon, RY. 2008. Front Biosci. 13: 5016-29. PMID: 18508566
- CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2. | García-Limones, C., et al. 2016. Oncogene. 35: 4289-301. PMID: 26751770
- Chk2 deficiency alleviates irradiation-induced taste dysfunction by inhibiting p53-dependent apoptosis. | Yuan, Z., et al. 2018. Oral Dis. 24: 856-863. PMID: 29292572
- CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer. | Zhao, W., et al. 2018. Cell Physiol Biochem. 45: 1590-1602. PMID: 29486482
- ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. | Ronco, C., et al. 2017. Medchemcomm. 8: 295-319. PMID: 30108746
- SIRT1 modulates cell cycle progression by regulating CHK2 acetylation-phosphorylation. | Zhang, W., et al. 2020. Cell Death Differ. 27: 482-496. PMID: 31209362
- Chk2-dependent phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) regulates centrosome maturation. | Nai, S., et al. 2019. Cell Cycle. 18: 2651-2659. PMID: 31416392
- AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR-CHK2 interaction and prostate cancer survival. | Ta, HQ., et al. 2020. Elife. 9: PMID: 32579110
- The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer. | Yu, P., et al. 2021. Oncogene. 40: 5262-5274. PMID: 34244606
- Nanoparticle-Mediated PRDX2 Inhibition for Specific Targeting of CHK2-Null Colorectal Cancer. | Ahmad, A., et al. 2022. ACS Biomater Sci Eng. 8: 5210-5220. PMID: 36446128
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Chk2 Antibody (DCS-270) | sc-56296 | 200 µg/ml | $322.00 | |||
Chk2 Antibody (DCS-270): m-IgGκ BP-HRP Bundle | sc-553182 | 200 µg Ab; 40 µg BP | $361.00 | |||
Chk2 Antibody (DCS-270): m-IgG2a BP-HRP Bundle | sc-553183 | 200 µg Ab; 10 µg BP | $361.00 |